American Journal of Cardiology
Volume 104, Issue 6 , Pages 840-845 , 15 September 2009

Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis†

  • William B. White, MD

      Affiliations

    • Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut
    • Corresponding Author InformationCorresponding author: Tel: 860-679-2104; fax: 860-679-1250
    • ,
  • Thomas J. Schnitzer, MD, PhD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Rosanna Fleming, MS

      Affiliations

    • Clinical Development & Medical Affairs, NicOx S.A., Sophia-Antipolis, France
    • NicOx, Inc., Warren, New Jersey
    • ,
  • Brigitte Duquesroix, MD

      Affiliations

    • Clinical Development & Medical Affairs, NicOx S.A., Sophia-Antipolis, France
    • NicOx, Inc., Warren, New Jersey
    • ,
  • Maarten Beekman, MD

      Affiliations

    • Clinical Development & Medical Affairs, NicOx S.A., Sophia-Antipolis, France
    • NicOx, Inc., Warren, New Jersey

Received 4 April 2009 ,Revised 5 May 2009 ,Accepted 5 May 2009.

References 

  1. Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum. 2005;53:827–837
  2. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375–3378
  3. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(suppl):S193–S201
  4. Medical Dictionary for Regulatory Activities Terminology: Version 9.1. Reston, Virginia: Maintenance and Support Services Organization; 2006;
  5. Whelton A, White WB, Bello AE, Puma JA, Fort JG SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959–963
  6. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:1161–1167
  7. Muscara MN, McKnight W, Del Soldato P, Wallace JL. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci. 1998;62:235–240
  8. Lohmander LS, McKeith D, Svensson O, Malmenas M, Bolin L, Kalla A, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005;64:449–456
  9. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007;49:408–418
  10. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension. 2004;43:574–577
  11. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929–934
  12. Houston MC, Weir M, Gray J, Ginsberg D, Szeto C, Kaihlenen PM, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med. 1995;155:1049–1054
  13. Klassen DK, Jane LH, Young DY, Peterson CA. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens. 1995;8:146–153
  14. MacDonald TM, Reginster JY, Littlejohn TW, Richard D, Lheritier K, Krammer G, et al. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens. 2008;26:1695–1702
  15. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–484
  16. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? (A meta-analysis). Ann Intern Med. 1994;121:289–300
  17. Grover SA, Coupal L, Zowall H. Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: what are the benefits of avoiding blood pressure destabilization?. Hypertension. 2005;45:92–97
  18. White WB. Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med. 2000;160:149–150
  19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  20. McInnis NH, Fodor G, Lum-Kwong MM, Leenan FH. Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). Am J Hypertens. 2008;21:1210–1215

PII: S0002-9149(09)01049-2

doi: 10.1016/j.amjcard.2009.05.014

American Journal of Cardiology
Volume 104, Issue 6 , Pages 840-845 , 15 September 2009

Article Tools

* Image Usage & Resolution